Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Aquestive rapeutics

Benzinga's Top Ratings Upgrades, Downgrades For August 30, 2022

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session

Aquestive Therapeutics Earnings Perspective: Return On Capital Employed

Aquestive Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Aquestive Therapeutics's (NASDAQ:AQST) reported sales totaled $12.27 million. Despite a 54.33% increase in earnings, the company posted a loss of $13.22 million.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Earnings Outlook For Aquestive Therapeutics

Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Aquestive Therapeutics will report an earnings per share (EPS) of $-0.41.

Looking Into Aquestive Therapeutics's Return On Capital Employed

Benzinga Pro data, Aquestive Therapeutics (NASDAQ:AQST) reported Q4 sales of $11.08 million. Earnings fell to a loss of $28.95 million, resulting in a 98.87% decrease from last quarter.

A Preview Of Aquestive Therapeutics's Earnings

Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-03-08. Here's what investors need to know before the announcement. Analysts estimate that Aquestive Therapeutics will report an earnings per share (EPS) of $-0.47.

1

Organisations

Lockheed Martin

Northrop Grumman

General Dynamics

L3Harris Technologies

Leidos Holdings

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play